Hoffmann-la Roche Inc.

Roche Palo Alto LLC

F. Hoffmann-la Roche Ag

Henrietta Dehmlow

Johannes Aebi

Olivier Morand

Jean Ackermann

Narendra Panday

Matthew Wright

Bernd Kuhn

Ulrike Obst Sander

Alexander Chucholowski

Hans G Richter

Hasane Ratni

Rainer Eugen Martin

Hans-Peter Maerki

Thomas Weller

Sabine Wallbaum

Caterina Bissantz

Shawn David Erickson

Tanja Schulz-Gasch

Patrizio Mattei

Uwe Grether

Raffaello Masciadri

Kyungjin Kim

Sherrie Lynn Pietranico-Cole

Christoph Ullmer

Robert Narquizian

Eric Argirios Kitas

Daniel Bur

Constantinos G Panousis

Nicole A Kratochwil

Jens-Uwe Peters

Stephan Roever

Ulrike Obst

Hans Lengsfeld

Jacques Himber

Denise Blum

Holger Kuehne

Georges Hirth

Hans Peter Wessel

Fabienne Ricklin

Aurelia Conte

Gerard Schmid

Rene Trussardi

Prabha Saba Karnachi

Yu-Hua Ji

Elisabeth Von Der Mark

Synese Jolidon

Konrad H Bleicher

Rene Wyler

Minmin Yang

Eric Joseph Niesor

Gregory Martin Benson

Bernd Michael Loeffler

Franz Schuler

Hans-Peter Marki

Xavier Marie Warot

G&eacute;rard Schmid

Syn&egrave;se Jolidon

Christoph Ulmer

Ku-Hua Ji

René Wyler

Constantinos Panousis

This invention relates to novel 3-aminopyridines of the formula wherein B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

3-amino-pyridines as GPBAR1 agonists

This invention relates to 1-pyridazinyl-hydroxyimino-3-phenyl-propanes of the formula wherein Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.

1-pyridazinyl-hydroxyimino-3-phenyl-propanes

This invention relates to novel 3-aminopyridines of the formula 

This invention relates to novel 1-hydroxyimino-3-phenyl-propanes of the formula wherein Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may be used as medicaments for the treatment of diseases such as type II diabetes.

1-hydroxyimino-3-phenyl-propanes

This invention relates to novel 1,2-pyridazines, 1,6-pyridazines or pyrimidines of the formula 

1,2-pyridazines, 1,6-pyridazines and pyrimidines

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A, A, B, Band Rto Rare as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds

Substituted pyridines as GPBAR1 agonists

The invention is concerned with novel piperazine amide derivatives of formula (I) wherein Rto R, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Piperazine amide derivatives

The invention is concerned with novel imidazolidine derivatives of formula (I) wherein Rto R, A, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Imidazolidine derivatives

The invention is concerned with novel biaryl sulfonamide derivatives of formula (I) wherein Rto Rand Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Biaryl sulfonamide derivatives

The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein Rto R, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.

Anthranilic acid derivatives

The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I): wherein R, R, R, R, R, X, X, X, Y, Z, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used in treating or preventing diseases which are modulated by HM74A agonists.

Aza-pyridopyrimidinone derivatives

The present invention relates to compounds of the formula (I) wherein R, R, R, R, R, X, X, X, X, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXR&#x3b1; and/or LXR&#x3b2; agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

Tetrahydrocarbazoles and derivatives

The invention is concerned with novel hexafluoroisopropanol derivatives of formula (I) wherein Rto R, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Hexafluoroisopropanol derivatives

Growing community of inventors

Grenzach-Wyhlen, Germany

Henrietta Dehmlow